Published in AAPS J on October 24, 2005
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Cannabinoid pharmacology: the first 66 years. Br J Pharmacol (2006) 1.73
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem (2010) 1.49
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol (2007) 1.27
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol (2010) 1.19
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res (2008) 1.08
Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol (2010) 1.03
Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) (2009) 1.01
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci (2009) 0.99
β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry (2012) 0.97
Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One (2008) 0.92
Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorg Med Chem Lett (2007) 0.92
Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis. Epilepsia (2009) 0.89
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol (2008) 0.89
Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. Br J Pharmacol (2011) 0.89
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol (2012) 0.87
β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol (2014) 0.87
A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. Neuropsychopharmacology (2015) 0.87
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. ACS Med Chem Lett (2012) 0.86
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) (2006) 0.86
Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. Psychopharmacology (Berl) (2007) 0.85
Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology (2008) 0.85
The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci (2013) 0.84
Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain. Brain Res (2011) 0.84
Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One (2012) 0.83
Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol. Alcohol Res Health (2008) 0.82
Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis (2009) 0.80
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. Proc Natl Acad Sci U S A (2012) 0.80
The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS One (2013) 0.80
Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases. Am J Physiol Heart Circ Physiol (2008) 0.80
Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J Med Chem (2014) 0.79
2-arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors. Br J Clin Pharmacol (2010) 0.79
Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol (2007) 0.78
Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging. Front Neurosci (2016) 0.78
Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors. PLoS One (2012) 0.78
Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorg Med Chem (2015) 0.77
Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception. Pharmacol Biochem Behav (2011) 0.77
Endocannabinoids in neuroendopsychology: multiphasic control of mitochondrial function. Philos Trans R Soc Lond B Biol Sci (2012) 0.77
Tissue Engineering of Cartilage; Can Cannabinoids Help? Pharmaceuticals (Basel) (2010) 0.75
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Control of pain initiation by endogenous cannabinoids. Nature (1998) 4.73
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 3.16
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther (2004) 2.99
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain (2004) 2.94
Cannabinoids: potential anticancer agents. Nat Rev Cancer (2003) 2.87
Pharmacological actions of cannabinoids. Handb Exp Pharmacol (2005) 2.56
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Cannabinoid receptors and pain. Prog Neurobiol (2001) 2.48
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Pharmacology of cannabinoid receptor ligands. Curr Med Chem (1999) 2.34
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A (1999) 2.31
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci (2004) 2.29
Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci (2004) 2.25
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci (2003) 2.25
Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology (2005) 2.24
Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A (2004) 2.23
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem (2001) 2.19
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler (2004) 2.15
Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids (2002) 2.15
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett (2000) 2.11
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler (2004) 2.08
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet (2000) 2.07
Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci (2003) 2.04
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J (1998) 1.89
Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol (2005) 1.84
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ (2004) 1.84
Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol (2003) 1.84
Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron (2003) 1.80
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 1.77
Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia (1997) 1.77
Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 1.76
Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci (2005) 1.70
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res (1991) 1.67
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol (2003) 1.66
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem (2001) 1.57
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience (2001) 1.57
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med (2005) 1.56
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 1.55
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J (2000) 1.55
The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol (2000) 1.50
Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat (2000) 1.50
The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther (1975) 1.49
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res (2001) 1.49
Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol (2004) 1.49
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 1.48
Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res (2005) 1.47
Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci (2003) 1.47
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci (2005) 1.43
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther (2002) 1.43
The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract (2005) 1.42
Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol (1975) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett (1997) 1.39
The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol (2004) 1.38
Elevated endogenous cannabinoids in schizophrenia. Neuroreport (1999) 1.38
The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol (2005) 1.38
Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol (2001) 1.35
Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology (2001) 1.35
Synergistic interactions between cannabinoid and opioid analgesics. Life Sci (2004) 1.35
Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol (2004) 1.34
Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids (2002) 1.34
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci (2004) 2.29